Durect Corporation (NASDAQ NM:DRRX) interessant, oder nicht !!! - 500 Beiträge pro Seite

[js200]

DURECT Corporate Event - Abstract

Tuesday , March 15, 2005 08:06 ET

Mar 15, 2005 (CORPORATE CONFERENCE CALL ABSTRACTS via COMTEX) --The DURECT Corporation (DRRX) Corporate Conference Call took place on 14-Mar-05 4:00pm ET

DRRX has signed an agreement with Endo Pharmaceuticals giving Endo license to develop and commercialize Sufentanil-containing transdermal patch in the US and Canada. Endo will assume all development, regulatory, sales, marketing, manufacturing, and launch costs. DRRX retains co-promotion rights and rights to all non-US and non-Canadian territories. The focus of the questions and answers session included cash burn, products in pipeline, and European market.

More information on this Conference Call can be obtained from Research and Markets at http://www.researchandmarkets.com/transcripts/56037

This document provides a non-biased summary of the conference call detailing the key points and the full Q&A session.

(Distributed for Research and Markets via M2 Communications Ltd (www.m2.com))

(C)2005 Research and Markets (http://www.researchandmarkets.com/).

[js200]

Last Trade: 3.520 Change: -0.190 (-5.121%)
Previous Close: 3.710 Volume: 159,900
Bid: 3.500 Ask: 3.510
Today`s Open: 3.790 # of Trades: 92


JS200

[BrauchGeld]

Hallo

Drrx gefällt mir gut ein einstieg sollte sich hier langfristig auszahlen.

Drrx hat genug geld (60mio$) und gute produkte.
BB Biotech hält auch einige aktien von Drrx.

Mk:170mio$
Kurs:3,40$
Pipeline:
http://www.durect.com/wt/durect/page_name/development

www.durect.com

[BrauchGeld]

Hallo

Die Aktie hat heute ein neues 52w hoch erreicht bei 4$,mir gefällt vor allem das die von der Chef-etage eigene aktien kaufen.

25-May-05 NEUKERMANS, ARMAND
Director 13,800 Purchase at $3.4599 per share. $47,746
24-May-05 NEUKERMANS, ARMAND
Director 61,200 Purchase at $3.4624 per share. $211,898
19-May-05 BENITO, SIMON X.
Director 5,000 Purchase at $3.27 per share. $16,350
11-May-05 BENITO, SIMON X.
Director 5,000 Purchase at $3.05 per share. $15,250
10-May-05 THEEUWES, FELIX
Chairman 40,000 Purchase at $2.89 - $2.99 per share. $118,0002

[BrauchGeld]

Hallo

Durect hatte ich zu 6,80$ verkauft,hätte gar nicht mehr damit gerechnet das die Aktie so tief fällt.
Bin wieder zu 5,45$ wieder dabei ,Drrx ist ein strong buy unter 6$.


Pipeline:
http://www.durect.com/wt/durect/page_name/development

[BrauchGeld]

Ich denke hier wird es schnell wieder über die 7$ gehen.
Durect besitzt eine traumhafte Pipeline und genug Cash.

UPDATE 2-King Pharma, Pain Therapeutics team on drug
Thu Nov 10, 2005 01:28 PM ET
(Updates with share prices, analyst comment, company comment)
NEW YORK, Nov 10 (Reuters) - King Pharmaceuticals Inc.(KG.N: Quote, Profile, Research) said on Thursday it has partnered with Pain Therapeutics Inc.(PTIE.O: Quote, Profile, Research) to develop and sell a long-acting, abuse-resistant form of the painkiller Oxycontin.

King will pay $150 million upfront in cash for rights to the Pain Therapeutics drug, Remoxy. If it were approved, Pain Therapeutics would receive additional payments of up to $150 million, depending on sales.

King will also pay for research and development of the drug, which the companies said could be as much as $100 million.

King`s stock fell $1.05 or more than 6 percent to $15.95 in afternoon trading amid concern that the company is overpaying for the drug. Shares of Pain Therapeutics rose $2.31 or over 36 percent to $8.65.

Shares of medical technology company Durect Corp. (DRRX.O: Quote, Profile, Research) , which would receive a royalty on the drug, rose 32 cents or 6 percent to $5.55 on Nasdaq.

"People think King paid a lot," said Scott Henry, an analyst at Oppenheimer & Co. Inc. "Between royalties and upfront payments, they paid about $150 million more than we had expected." Henry owns King stock.

Oxycontin, which is now sold generically, generated sales of about $2 billion over the last year. Remi Barbier, chief executive of Pain Therapeutics, said he expects the new drug to claim 80 percent to 90 percent of that market, if approved. And he expects the market as a whole to grow by 20 percent within three years of approval.

Henry`s estimate is far lower. He predicts the drug would achieve peak sales of $500 million by 2015.

Pain Therapeutics will shortly enroll patients in a late-stage, or Phase III, trial of the drug for the treatment of moderate-to-severe chronic pain. The companies expect the trial to be completed by December 2006. If successful, an application to market the drug would be filed with U.S. regulators in 2007.

King would be competing in the painkiller market with Endo Pharmaceuticals Holdings Inc. (ENDP.O: Quote, Profile, Research) , which said earlier this year that its experimental long-acting form of Oxycontin, which is made by Purdue Pharma LP, was effective in a late-stage trial and is awaiting regulatory approval. Endo shares were off 3 cents to $28.25.

Endo`s drug, oxymorphone ER, contains an altered form of the active ingredient in Oxycontin -- which is often abused by users, who crush the tablets to disrupt the pill`s time-release process and get high. (Additional reporting by Julie Steenhuysen)

[js200]

11/08/2005 (21:15 ET) DRRX: New Form 4 Filed, Change in Beneficial Ownership - Edgar
11/08/2005 (21:00 ET) DRRX: New Form 4/A Filed, Change in Beneficial Ownership - Edgar
11/08/2005 (20:05 ET) DRRX: New Form 4 Filed, Change in Beneficial Ownership - Edgar
11/08/2005 (09:32 ET) DRRX: To Present At BIO-Europe 2005 Conference @ 11:30 ET - Knobias
11/08/2005 (08:32 ET) DRRX: To Present At CIBC Healthcare Conference @ 10:30 ET - Knobias

[BrauchGeld]

Gute Nachrichten

DURECT Highlights Major Commercial Strategic Alliance for ORADUR(TM) Sustained Release Oral Gel-cap Technology
Friday November 11, 6:30 am ET


CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX - News) announced the validation of the commercial potential of its ORADUR(TM) sustained release oral gel-cap technology with the recently announced strategic alliance to develop and commercialize Remoxy(TM), an ORADUR-based novel long-acting, abuse-deterrent oral formulation of oxycodone and other ORADUR-based products candidates using three other opioid drugs. On November 10, 2005, King Pharmaceuticals, Inc. and Pain Therapeutics, Inc. announced that the companies have entered into a strategic alliance to develop and commercialize Remoxy and other ORADUR-based abuse-deterrent products using three other opioid drugs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )

"We are very pleased to have King Pharmaceuticals endorse the commercial potential for products based on our ORADUR platform technology. We are excited to have a strong commercial organization such as King Pharmaceuticals responsible for the commercialization of these products. This collaboration is just one example of pharmaceutical companies looking for unique products based on novel, patented technology platforms such as ours to address large and growing unmet medical needs," stated James E. Brown, DVM, President and Chief Executive Officer.

"We look forward to working with King and Pain Therapeutics to bring Remoxy and these other long-acting opioid drugs to the marketplace and generating significant value from these products for our shareholders. Furthermore, we look forward to developing additional innovative sustained release oral gel-cap products that utilize other opioids and other active agents prone to abuse."

"King is highly committed to making Remoxy and the three follow-on ORADUR-opioid products a commercial success. We believe that this represents a great market opportunity based upon the unmet medical need for narcotics with reduced abuse potential," stated Brian Markison, President and Chief Executive Officer of King Pharmaceuticals, Inc

[Eymen]

Habt Ihr Schlaftablette genommen oder was.!
Das sollte ich auch machen